908 Devices Inc. (NASDAQ:MASS – Get Free Report) has been given an average rating of “Buy” by the four research firms that are currently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $8.00.
MASS has been the subject of a number of recent analyst reports. Leerink Partners raised 908 Devices from a “market perform” rating to an “outperform” rating and set a $12.00 target price for the company in a report on Tuesday, August 5th. Wall Street Zen raised 908 Devices from a “sell” rating to a “hold” rating in a report on Monday, September 15th. Leerink Partnrs raised 908 Devices from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 908 Devices in a report on Saturday, September 13th.
Get 908 Devices alerts:
Get Our Latest Stock Analysis on 908 Devices
908 Devices Stock Performance
Shares of MASS opened at $8.76 on Friday. The business has a 50-day moving average of $6.60 and a 200 day moving average of $5.93. 908 Devices has a fifty-two week low of $1.81 and a fifty-two week high of $8.79. The firm has a market cap of $314.13 million, a P/E ratio of -16.22 and a beta of 0.37.
908 Devices (NASDAQ:MASS – Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.02). 908 Devices had a negative return on equity of 24.30% and a negative net margin of 30.54%.The firm had revenue of $4.70 million during the quarter, compared to analysts’ expectations of $12.17 million. 908 Devices has set its FY 2025 guidance at EPS. As a group, research analysts predict that 908 Devices will post -1.99 earnings per share for the current fiscal year.
Insider Activity
In other news, CFO Joseph H. Iv Griffith sold 5,000 shares of 908 Devices stock in a transaction dated Friday, September 19th. The stock was sold at an average price of $7.07, for a total transaction of $35,350.00. Following the completion of the sale, the chief financial officer owned 97,930 shares in the company, valued at approximately $692,365.10. This trade represents a 4.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 23.70% of the company’s stock.
Institutional Trading of 908 Devices
A number of large investors have recently modified their holdings of the business. AWM Investment Company Inc. lifted its position in 908 Devices by 210.6% in the 1st quarter. AWM Investment Company Inc. now owns 5,199,924 shares of the company’s stock worth $23,296,000 after buying an additional 3,526,000 shares during the last quarter. ARK Investment Management LLC lifted its position in 908 Devices by 4.0% in the 1st quarter. ARK Investment Management LLC now owns 2,899,347 shares of the company’s stock worth $12,989,000 after buying an additional 110,781 shares during the last quarter. First Light Asset Management LLC bought a new stake in 908 Devices in the 1st quarter worth approximately $7,621,000. GM Advisory Group LLC bought a new stake in 908 Devices in the 2nd quarter worth approximately $8,309,000. Finally, Geode Capital Management LLC lifted its position in 908 Devices by 11.7% in the 2nd quarter. Geode Capital Management LLC now owns 658,603 shares of the company’s stock worth $4,697,000 after buying an additional 68,764 shares during the last quarter. Institutional investors own 88.06% of the company’s stock.
908 Devices Company Profile
(Get Free Report)
908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company’s products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.
Read More
Five stocks we like better than 908 Devices
Airline Stocks – Top Airline Stocks to Buy Now
PayPal Stock: Why Wall Street May Be Undervaluing This Giant
Retail Stocks Investing, Explained
Why Vertical Aerospace Could Lead the eVTOL Market by 2028
Pros And Cons Of Monthly Dividend Stocks
Is Draganfly’s Army Partnership a Game-Changer for Investors?